Our commitment to lung health is built on deep scientific expertise, especially in inflammation and fibrosis, driving the development of next-generation therapies.

For more than 100 years, we have pioneered treatments across lung diseases like COPD, asthma and pulmonary fibrosis and we won’t stop here. We remain dedicated to addressing the unmet need of people living with lung diseases by targeting scientific breakthroughs that aim to restore lung health and prevent diseases like pulmonary fibrosis.

We are also expanding our research into other lung conditions including bronchiectasis, the third most common chronic inflammatory lung disease after COPD and asthma, yet still severely underdiagnosed.

Xentria is a clinical-stage biopharmaceutical company dedicated to developing therapies for patients with rare and underserved diseases. Our mission is to advance science-driven therapeutics that address conditions where treatment options remain limited and patient burden is high.

A core focus of Xentria’s pipeline is the complex, multi-system inflammatory condition known as sarcoidosis.

XTMAB-16, Xentria’s lead investigational monoclonal antibody, is currently being evaluated in a clinical trial (XTMAB16-201) in patients with pulmonary sarcoidosis. XTMAB-16 is designed to target tumor necrosis factor alpha (TNF-α), a cytokine implicated in granuloma formation and persistent inflammation in sarcoidosis.

Through disciplined clinical development, close collaboration with sarcoidosis experts, and engagement with the sarcoidosis community, Xentria is committed to advancing therapeutic options that may improve outcomes and quality of life for patients living with this challenging rare disease.